FASpecT/CT, A New SPECT/CT Acquisition With Higher Sensitivity and Efficiency in Radioiodine Thyroid Cancer Imaging

Clin Nucl Med. 2020 May;45(5):356-364. doi: 10.1097/RLU.0000000000002978.

Abstract

Purpose: This article demonstrates the use of a new SPECT/CT acquisition protocol in patients with differentiated thyroid cancer (DTC).

Methods: SPECT/CT scans (FASpecT/CT) with fewer angle acquisitions were retrospectively reviewed in 30 DTC patients treated with radioiodine at University Hospital, San Antonio, Tex, from July 2017 to March 2019. This FASpecT/CT of 12 versus 60 to 64 sampled views for convention SPECT was made possible by iterative reconstruction.

Results: The FASpecT/CT protocol was judged to increase lesion detection in patients with low count rates. Furthermore, in patients with higher count rates, this technique reduced the acquisition time. FASpecT/CT patient images are shown as case examples in 4 of the 30 patients reviewed.

Conclusions: This FASpecT/CT acquisition in radioiodine-treated DTC offers the potential of higher sensitivity for metastatic lymph node detection in low count rates and a significant decrease in imaging time in high count rates. These advantages make SPECT/CT imaging more acceptable for patients who have difficulty with longer imaging times, to include the pediatric population.

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Iodine Radioisotopes
  • Male
  • Middle Aged
  • Radiopharmaceuticals
  • Sensitivity and Specificity
  • Single Photon Emission Computed Tomography Computed Tomography / methods*
  • Single Photon Emission Computed Tomography Computed Tomography / standards
  • Thyroid Neoplasms / diagnostic imaging*

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals